Skip to main content
S&P 5007,805.45-0.08%DOW51,670.10+0.03%NASDAQ27,204.38-0.15%BTC$83,383.00+2.60%ETH$2,506.39+3.61%GOLD$4,179.30+0.05%OIL$94.91+0.82%
Smart Investors Daily
SID Premium
EL

NASDAQ · ELDN

Eledon Pharmaceuticals, Inc.

Healthcare · Biotechnology

$2.34

Down-$0.10 (-4.10%)

Updated Oct 14, 2026, 2:21 AM

SID Score

3.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
102.42M
P/E ratio
-1.65
Dividend yield
0.00%
52-week range
$2.36 – $4.49
Volume
1.17M
Avg. volume
2.2M

Price performance · ELDN

ELDN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 13, 2026

ELDN closed at $2.34 after 21 trading sessions, down 13.65% for the selected period.

Last close
$2.34
Period change
-13.65%
Period low
$2.34
Period high
$2.89
Daily close
View OHLC price history
ELDN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 13, 2026$2.49$2.49$2.32$2.341.17M
Oct 12, 2026$2.50$2.58$2.425$2.44440.6K
Oct 9, 2026$2.42$2.5555$2.42$2.48818.75K
Oct 8, 2026$2.40$2.44$2.36$2.42834.62K
Oct 7, 2026$2.42$2.48$2.39$2.42583.6K
Oct 6, 2026$2.53$2.56$2.42$2.45830.33K
Oct 5, 2026$2.53$2.57$2.45$2.50725.9K
Oct 2, 2026$2.48$2.55$2.42$2.49973.16K
Oct 1, 2026$2.52$2.55$2.425$2.435616.5K
Sep 30, 2026$2.53$2.62$2.50$2.53717.49K
Sep 29, 2026$2.64$2.64$2.49$2.50712.52K
Sep 28, 2026$2.65$2.66$2.53$2.64714.55K
Sep 25, 2026$2.68$2.685$2.62$2.65620.06K
Sep 24, 2026$2.72$2.771$2.60$2.681.03M
Sep 23, 2026$2.90$2.94$2.685$2.721.32M
Sep 22, 2026$2.75$3.09$2.68$2.892.1M
Sep 21, 2026$2.74$2.74$2.59$2.69609.85K
Sep 18, 2026$2.67$2.68$2.57$2.62828.99K
Sep 17, 2026$2.73$2.79$2.615$2.65558.4K
Sep 16, 2026$2.71$2.724$2.64$2.67738.77K
Sep 15, 2026$2.79$2.81$2.655$2.71806.31K

Latest ELDN news

The latest Smart Investors Daily articles mentioning ELDN.

Stock researchCompany · Overview

ELDN research

Overview

Company profile and research snapshot.

Company profile

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$9.00
Implied upside
—
Analysts
—
ELDN recent ratings
DateFirmRatingTarget
Jul 21, 2026Rodman & RenshawBuy—
Nov 18, 2025GuggenheimBuy—
Sep 2, 2025HC Wainwright & Co.Buy—
Jul 25, 2025Craig-HallumBuy—
Nov 20, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 5, 2026

Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting

IRVINE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation will be featured at the upcoming American Society of Nephrology Kidney Week 2026 Annual Meeting taking place in Denver, CO, from October 21-25, 2026. The oral presentation will highlight patient-reported outcomes from the Phase 2 BESTOW trial evaluating tegoprubart for the prevention of rejection in kidney transplantation. Details of the presentation are b

Yahoo · Sep 22, 2026

Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society

Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus tacrolimus (71 vs. 58 mL/min/1.73 m²) at month 24 No rejections occurred in the tegoprubart arm beyond six months post-transplant, compared with seven in the tacrolimus arm Tegoprubart granted U.S. FDA Fast Track designation for the prevention of rejection in kidney transplantation Phase 3 LEGACY study expe

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By